Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun;12(2):142-53.
doi: 10.1007/s11914-014-0204-5.

Therapies for musculoskeletal disease: can we treat two birds with one stone?

Christian M Girgis  1 , Nancy Mokbel, Douglas J Digirolamo
Affiliations
Review

Therapies for musculoskeletal disease: can we treat two birds with one stone?

Christian M Girgis et al. Curr Osteoporos Rep. 2014 Jun.

Abstract

Musculoskeletal diseases are highly prevalent with staggering annual health care costs across the globe. The combined wasting of muscle (sarcopenia) and bone (osteoporosis)-both in normal aging and pathologic states-can lead to vastly compounded risk for fracture in patients. Until now, our therapeutic approach to the prevention of such fractures has focused solely on bone, but our increasing understanding of the interconnected biology of muscle and bone has begun to shift our treatment paradigm for musculoskeletal disease. Targeting pathways that centrally regulate both bone and muscle (eg, GH/IGF-1, sex steroids, etc.) and newly emerging pathways that might facilitate communication between these 2 tissues (eg, activin/myostatin) might allow a greater therapeutic benefit and/or previously unanticipated means by which to treat these frail patients and prevent fracture. In this review, we will discuss a number of therapies currently under development that aim to treat musculoskeletal disease in precisely such a holistic fashion.

PubMed Disclaimer

References

    1. Australian Bureau of Statistics [Accessed Dec 2013];2005 Available at: http://www.abs.gov.au/ausstats/abs@.nsf/cat/4823.0.55.001.
    1. Connelly LB, Woolf A, Brooks P. Cost-effectiveness of interventions for musculoskeletal conditions. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., editors. Disease control priorities in developing countries. 2nd edn. Oxford University Press and World Bank; Washington, DC: 2006. pp. 963–8. - PubMed
    1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726–33. doi:10.1007/s00198-006-0172-4. - PubMed

    1. Bonewald LF, Kiel DP, Clemens TL, Esser K, Orwoll ES, O’Keefe RJ, et al. Forum on bone and skeletal muscle interactions: summary of the proceedings of an ASBMR workshop. J Bone Miner Res. 2013;28(9):1857–65. doi:10.1002/jbmr.1980. This perspective article summarizes an ASBMR workshop on bone-muscle interactions, outlines current concepts in the field, and research questions to stmulate potential therapeutic strategies for musculoskeletal disorders.

    1. Cooper C, Dere W, Evans W, Kanis JA, Rizzoli R, Sayer AA, et al. Frailty and sarcopenia: definitions and outcome parameters. Osteoporos Int. 2012;23(7):1839–48. doi:10.1007/s00198-012-1913-1. - PubMed

Publication types

MeSH terms

LinkOut - more resources